ArticleArchives of toxicology2025
Genetic alterations in coronary cell lines exposed to sirolimus and paclitaxel.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioplasties using drug-eluting stents remain the most common and effective intervention for coronary artery disease. However, in-stent restenosis (ISR) continues to be the leading cause of stent failure following percutaneous coronary intervention, accounting for 5-10% of all clinical intervention procedures. This study aimed to investigate the potential molecular mechanisms involved in the development of in-stent restenosis. The cytotoxicity, genotoxicity, and transcriptional changes induced by sirolimus, paclitaxel, and mechanical stress were assessed in human coronary artery endothelial and smooth muscle cell lines. Both drugs were similarly effective in suppressing cell growth in these cell lines at different stages of the cell cycle. However, while paclitaxel primarily induced apoptosis, sirolimus caused cell death mainly through necrosis. Additionally, both drugs exhibited genotoxic effects, primarily increasing the levels of oxidized DNA nucleotide bases. Transcriptome analysis identified 23 differentially expressed genes with known biological functions in the chemically treated groups. Interestingly, transcriptomic alterations were also observed in coronary cells subjected solely to mechanical stress. In conclusion, our data confirm that sirolimus and paclitaxel inhibit cell proliferation through distinct mechanisms. Nonetheless, their genotoxic potential appears to act as a stimulus for cell proliferation, thereby increasing the risk of restenosis.
Indexed as
Identifiers
40481235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.